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1990 94, after the diagnosis of OI, one-year survival
probability is only 59.8% (95%CI 52.0 67.7%). The most
common OI’s are tuberculosis (40 50%), cryptococcosis
(25 40%), Pneumocystis carinii pneumonia PCP (10 20%),
toxoplasmosis (5 10%) and salmonellosis (5 10%). In the
northern part of Thailand, where Penicillium marneffei
is endemic, this infection is as common as tuberculosis,
indicating the importance of local endemic infection to be
recognized as AIDS-deﬁning illnesses. Cryptococcosis carries
the worst prognosis with 1-year survival probability of 31.9%
(16.8 48.1%).
Since HAART became available and ﬁnancially supported
by Thai Government in 2001, the morbidity and mortality
of HIV-infected persons have decreased remarkably. OI’s
has decreased and people living with AIDS/HIV survive
much longer. The emergence of drug-resistant HIV has
posed problems since the second line drugs are much more
expensive and not many to choose from. In addition, this
group can transmit drug-resistant HIV causing primary drug-
resistant HIV infection which will make it more difﬁcult to
choose the proper regimen without genotyping the virus.
Thus, strong prevention and control program should remain
at top priority, to stop new infection and transmission.
I-24 HIV-speciﬁc T-cell responses in a cohort of slow
progressors in China
T. Dong*. WIMM, Oxford University, United Kingdom
Background: There is an urgent need for an effective
vaccine to prevent HIV-1 infection, and current efforts are
directed towards generating vaccine candidates that will
elicit a T-cell immune response to the virus.. No studies
to date have described mechanisms of HIV resistance or
delayed disease progression in Chinese cohorts. For both
the design and the evaluation of CTL-inducing vaccines it is
important to deﬁne immunodominant CTL epitopes for both
the prevailing HLA types and the most common viral strains
affecting that population. Morever, it is also important to
identify composite features of T-cell responses associated
with good outcome and T-cell epitopes that will generate
such beneﬁcial features.
Study cohort: Current studies are limited by the facts that
most of the study cohort subjects have been infected for
different lengths of time; infected with different viral
strains and have a diverse genetic background. In this
study, we have access to a unique village cohort of patients
(N = 407) who were involved in a plasma donation scheme
that became contaminated with clade B HIV-1 in the period
1994 1995. 137 premature adult deaths were recorded in
the village with symptoms compatible with HIV-1 disease
before 2003. Of the surviving patients, none were treated
before 2003: therefore the proportion of slow or non-
progressors is unusually high in this cohort (>50% had CD4
counts >200 in 2004).
Results: We found that HLA-A30 and B51 were strongly
associated with low viral load in this cohort. We investigated
the hypothesis that immunodominant T-cell responses to
conserved HIV-1 proteins restricted by these alleles could
be partially responsible for good control of virus. We used
ELISPOT assays to test for responses to overlapping Clade B
peptides spanning the whole viral proteome and to the 202
best characterised optimal epitopes from the Los Alamos
data base. We found broad T cell responses, especially
directed towards the gag protein, in patients with low
viral loads. The immunodominance hierarchy of epitopes
restricted by common HLA molecules in the cohort showed
very different patterns from a published acute cohort
(Altfeld, 2006). We have sequenced the gag and nef genes
from 97 patients and will present data to show that the loss
of certain responses in the chronic phase of infection might
be due to early selection of escape mutants.
Conclusion: We have identiﬁed a panel of immunodominant
T-cell responses restricted by common HLA alleles in a
Chinese slow progressor cohort. Identiﬁcation of the most
beneﬁcial responses will be particular important for future
vaccine design targeted to the Chinese population.
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To combat the HIV/AIDS epidemic in China, the National
Center for AIDS/STD Control and Prevention established the
Division of Treatment and Care in late 2001. The pilot for
the National Free ART Program began in Henan Province in
2002, and the program fully launched in 2003. Initially,
treatment efforts focused on patients infected through
illicit blood and plasma donations in the mid-1990s, and
subsequently expanded to include HIV-infected injection
drug users, commercial sex workers, pregnant women, and
children. The National Free ART Database was established
in late 2004, and includes data on current patients and
those who were treated before 2004. Over 50,000 adult and
pediatric patients have been treated thus far. Challenges
for the program include integration of drug treatment
services with ART, an under-resourced health care system,
co-infections, stigma, discrimination, drug resistance, and
procurement of second-line ART. The merging of national
treatment and care, epidemiologic, and drug resistance
databases will be critical for a better understanding of the
epidemic, earlier identiﬁcation of patients requiring ART,
and improved patient follow-up. The Free ART Program has
made considerable progress in providing the necessary care
and treatment for HIV-infected people in China and has
strong government support for continued improvement and
expansion.
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I-26 Immunology of HBV infection
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HBV is an enveloped, hepatotrophic, oncogenic
hepadnavirus that infects hepatocytes and leukocytes
of humans and chimpanzees. The clinicopathological
outcomes of HBV infection are determined by both
viral and host factors. HBV infects hepatocytes without
triggering apoptosis, altering hepatocyte gene expression
or inducing innate immune production of IFNa or IFNb.
Host determinants of outcomes are the quality, quantity,
kinetics and immunoregulation of the integrated innate
and adaptive immune responses. HBV subverts the innate
immune response by down-regulating (1) expression of MICA,
the primary ligand for the NKG2D receptors of NK cells and
(2) TLR1, 2, 4 and 6 transcripts in PBMC. In addition, HBV
persistence and disease progression is favored by the low
production of mannose binding lectin (MBL) and reduction
in the interferon-inducible APOBEC3 family of cytidine
deaminases that inhibit HBV replication and hypermutate
the HBV genome. Generation of polyclonal, multi-antigen-
speciﬁc CD4 T-cell and CD8 cytotoxic T lymphocytes (CTL)
is required for resolution of acute HBV infection through
the combined effects of HBV-speciﬁc cytolysis of infected
